Holen Sie sich die Stockscreener-App
111.81
0.56%
0.945
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$110.87
Offen:
$111.5
24-Stunden-Volumen:
399.56K
Relative Volume:
0.04
Marktkapitalisierung:
$136.94B
Einnahmen:
$28.73B
Nettoeinkommen (Verlust:
$5.97B
KGV:
23.54
EPS:
4.75
Netto-Cashflow:
$9.84B
1W Leistung:
+4.00%
1M Leistung:
+1.28%
6M Leistung:
+20.70%
1J Leistung:
+62.43%
1-Tages-Spanne:
$110.84
$111.95
1-Wochen-Bereich:
$104.46
$112.00
52-Wochen-Spanne:
$66.01
$119.96
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Vergleichen Sie GILD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
111.92 | 136.94B | 28.73B | 5.97B | 9.84B | 4.75 |
|
LLY
Lilly Eli Co
|
782.35 | 724.64B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
153.51 | 376.43B | 89.33B | 21.81B | 18.57B | 8.99 |
|
NVO
Novo Nordisk Adr
|
68.34 | 352.49B | 43.59B | 15.04B | 10.74B | 3.3766 |
|
ABBV
Abbvie Inc
|
185.26 | 334.73B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
122.42 | 234.21B | 53.22B | 12.86B | 14.85B | 6.39 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Gilead Sciences Lands First FDA Approval of a Twice-a-Year HIV PrEP Drug - MedCity News
US FDA approves Gilead's twice-yearly injection for HIV prevention - Deccan Herald
US approves Gilead’s twice-yearly injection to prevent HIV - The Malaysian Reserve
US approves Gilead's twice-yearly injection to prevent HIV - El Paso Inc.
The world's only twice-a-year shot to prevent HIV could stop transmission — if people can get it - Shelton Herald
Gilead Sciences facility video - KTIV
HIV prevention drug lenacapavir approved by FDA as twice-yearly injection - CBS News
FDA approves Gilead's twice-yearly HIV prevention shot - FirstWord Pharma
Gilead Wins Historic Approval for Twice-Yearly HIV Drug - BioSpace
HIV advance: Twice-yearly shot to prevent infection - NZ Herald
Cautious Optimism for Gilead Sciences Amid Yeztugo’s Market Challenges - TipRanks
Gilead's twice-yearly PrEP drug is cleared by FDA - pharmaphorum
FDA approves twice-yearly shot of Gilead drug for HIV prevention - BioPharma Dive
Gilead's HIV Prevention Drug Is 99.9% Effective. Could Politics Derail It? - Investor's Business Daily
US Approves Gilead's Twice-yearly Injection To Prevent HIV - Barron's
FDA Approves Gilead’s Twice-Yearly Injection for HIV Prevention - The Well News
FDA approves 6-month HIV prevention shot - The Hill
Gilead's (GILD) HIV Treatment Yeztugo Gains FDA Approval, Market Potential Expands | GILD Stock News - GuruFocus
FDA Approval Boosts Gilead's (GILD) Prospects in HIV Prevention | GILD Stock News - GuruFocus
Gilead Sciences stock steady as FDA approves twice-yearly HIV prevention - Investing.com UK
Mizuho says Gilead Yeztugo label looks clean - TipRanks
Gilead Sciences (GILD) Gains FDA Nod for HIV Prevention Drug - GuruFocus
FDA Approves Gilead’s HIV Shot. It Works 99.9% of the Time. - Barron's
Gilead Sciences’ Yeztugo Approval and Market Expansion Drive Buy Rating - TipRanks
FDA approves powerful HIV prevention drug: What to know about Yeztugo - NBC News
FDA approves the world’s only twice-a-year shot to prevent HIV - mypanhandle.com
FDA Approves Gilead’s Twice-Yearly Injectable Lenacapavir (Yeztugo) for HIV Prevention - ContagionLive
Gilead’s twice-yearly PrEP injection wins FDA approval, analysts see solid launch ahead - Proactive financial news
Gilead Sciences' HIV Prevention Drug Yeztugo Receives FDA Approval - MarketScreener
Gilead (GILD) Gains FDA Approval for Unique HIV Prevention Drug Yeztugo | GILD Stock News - GuruFocus
Gilead announces FDA approves Yeztugo as twice-a-year HIV prevention option - TipRanks
Gilead’s Twice-a-Year HIV Prevention Shot Wins US FDA Approval - Bloomberg.com
Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection - marketscreener.com
Gilead's (GILD) Lenacapavir Advances as HIV Prevention Treatment - GuruFocus
Gilead (GILD) Gains FDA Approval for HIV Prevention Injection | - GuruFocus
Gilead’s twice-yearly HIV prevention shot gets FDA approval - Investing.com Australia
US FDA approves Gilead’s twice-yearly injection for HIV prevention By Reuters - Investing.com
Gilead’s twice-yearly HIV prevention shot gets FDA approval By Investing.com - Investing.com Canada
Gilead stock gains on FDA nod for HIV PrEP drug (GILD:NASDAQ) - Seeking Alpha
FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option - CNBC
Gilead won U.S. approval for HIV prevention shot, but when will low-income countries gain sufficient access? - STAT
FDA Says Gilead's Yeztugo Receives FDA Approval For HIV Prevention - marketscreener.com
Gilead Researcher Awarded the AAAS Mani L. Bhaumik Breakthrough of the Year Award - CSRwire
Buy, Sell, Or Hold GILD Stock? - Trefis
Gilead Sciences, Inc. (GILD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Fibrotic Diseases Treatment Market Top Companies StudyAbbVie - openPR.com
Gilead's HIV drug could end epidemic, but the company has a dark side - Fast Company
Insider Sell: Andrew Dickinson Sells 2,500 Shares of Gilead Sciences Inc (GILD) - GuruFocus
Gilead's HIV Prevention Drug Could Be Manufactured At Shocking Low Cost: ReportGilead Sciences (NASDAQ:GILD) - Benzinga
Gilead (GILD) Downplays FDA Decision to Pause HIV Combination Trial over Safety Concern - Insider Monkey
Levi & Korsinsky Investigates Gilead Sciences, Inc. (GILD) Over Possible Securities Fraud - ACCESS Newswire
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Gilead Sciences Inc-Aktie (GILD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Dickinson Andrew D | Chief Financial Officer |
Jun 16 '25 |
Sale |
110.17 |
2,500 |
275,425 |
165,110 |
| Mercier Johanna | Chief Commercial Officer |
Jun 16 '25 |
Sale |
110.17 |
3,000 |
330,510 |
120,168 |
0.33%
0.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):